Exploiting the inherent promiscuity of the acyl transferase of the stambomycin polyketide synthase for the mutasynthesis of analogues

Exploiting the inherent promiscuity of the acyl transferase of the stambomycin polyketide synthase for the mutasynthesis of analogues | bioRxiv /* */ /* */ <!-- <!-- /*! * yepnope1.5.4 * (c) WTFPL, GPLv2 */ (function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-M677548'); Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Exploiting the inherent promiscuity of the acyl transferase of the stambomycin polyketide synthase for the mutasynthesis of analogues View ORCID Profile Li Su , View ORCID Profile Yaouba Souaibou , Laurence Hôtel , View ORCID Profile Christophe Jacob , Peter Grün , View ORCID Profile Yan-Ni Shi , Alicia Chateau , View ORCID Profile Sophie Pinel , View ORCID Profile Helge B. Bode , View ORCID Profile Bertrand Aigle , View ORCID Profile Kira J. Weissman doi: https://doi.org/10.1101/2024.10.29.620781 Li Su a Université de Lorraine, CNRS, IMoPA , F-54000 Nancy, France b Université de Lorraine, INRAE, DynAMic , F-54000 Nancy, France c Max-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions , 35043 Marburg, Germany Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Li Su Yaouba Souaibou a Université de Lorraine, CNRS, IMoPA , F-54000 Nancy, France b Université de Lorraine, INRAE, DynAMic , F-54000 Nancy, France d IPHC, UMR 7178, CNRS, Université de Strasbourg, Equipe de Chimie Analytique des Molécules Bioactives et Pharmacognosie , Illkirch, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Yaouba Souaibou Laurence Hôtel b Université de Lorraine, INRAE, DynAMic , F-54000 Nancy, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christophe Jacob a Université de Lorraine, CNRS, IMoPA , F-54000 Nancy, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Christophe Jacob Peter Grün c Max-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions , 35043 Marburg, Germany Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yan-Ni Shi c Max-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions , 35043 Marburg, Germany f Molecular Biotechnology, Department of Biosciences, Goethe University Frankfurt , 60438 Frankfurt am Main, Germany Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Yan-Ni Shi Alicia Chateau e Université de Lorraine, CNRS, CRAN , F-54000 Nancy, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sophie Pinel e Université de Lorraine, CNRS, CRAN , F-54000 Nancy, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sophie Pinel Helge B. Bode c Max-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions , 35043 Marburg, Germany f Molecular Biotechnology, Department of Biosciences, Goethe University Frankfurt , 60438 Frankfurt am Main, Germany g Chemical Biology, Department of Chemistry, Philipps University of Marburg , 35043 Marburg, Germany h Senckenberg Gesellschaft für Naturforschung , 60325 Frankfurt am Main, Germany i Center for Synthetic Microbiology (SYNMIKRO), University of Marburg , 35043 Marburg, Germany Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Helge B. Bode Bertrand Aigle b Université de Lorraine, INRAE, DynAMic , F-54000 Nancy, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Bertrand Aigle For correspondence: bertrand.aigle{at}univ-lorraine.fr Kira J. Weissman a Université de Lorraine, CNRS, IMoPA , F-54000 Nancy, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kira J. Weissman For correspondence: bertrand.aigle{at}univ-lorraine.fr Abstract Full Text Info/History Metrics Supplementary material Preview PDF Abstract The polyketide specialized metabolites of bacteria are attractive targets for generating analogues, with the goal of improving their pharmaceutical properties. Here, we aimed to produce C-26 derivatives of the giant anti-cancer stambomycin macrolides using a mutasynthesis approach, as this position has been shown previously to directly impact bioactivity. For this, we leveraged the intrinsically broad specificity of the acyl transferase domain (AT 12 ) of the modular polyketide synthase (PKS), which is responsible for the alkyl branching functionality at this position. Feeding of a panel of synthetic and commercially available dicarboxylic acid ‘mutasynthons’ to an engineered strain of Streptomyces ambofaciens (Sa) deficient in synthesis of the native α-carboxyacyl-CoA extender units, resulted in six new series of stambomycin derivatives as judged by LC-HRMS and NMR. Notably, the highest product yields were observed for substrates which were only poorly accepted when AT 12 was transplanted into a different PKS module, suggesting a critical role for domain context in the overall functioning of PKS proteins. We also demonstrate the superiority of this mutasynthesis approach − both in terms of absolute titers and yields relative to the parental compounds − in comparison to the alternative precursor-directed strategy in which monoacid building blocks are supplied to the wild type strain. We further identify a malonyl-CoA synthetase, MatB_Sa, with specificity distinct from previously identified promiscuous enzymes, making it a useful addition to a mutasynthesis toolbox for generating atypical, CoA activated extender units. Finally, we show that two of the obtained (deoxy)-butyl-stambomycins exhibit antibacterial and antiproliferative activities similar to the parental stambomycins, while an unexpected butyl-demethyl congener is less potent. Overall, this works confirms the interest of biosynthetic pathways which combine a dedicated route to extender unit synthesis and a broad specificity AT domain for producing bioactive derivatives of fully-elaborated complex polyketides. Introduction The reduced polyketide specialized metabolites of bacteria exhibit stunning structural diversity. One source of this architectural variety is the multiple acyl-CoA building blocks incorporated during chain building. This construction process is carried out by mega-enzyme assembly lines called type I polyketide synthases (PKSs), which comprise a series of functional modules distributed among multiple polypeptide subunits. The modules are composed of sets of catalytic domains (minimally ketosynthase (KS) and acyl transferase (AT)) which act in partnership with non-catalytic acyl carrier proteins (ACPs) to elongate the chains, followed by optional modification of each newly-incorporated monomer. Both the ‘starter units’ which initiate the biosynthesis and the ‘extender units’ used in chain elongation are selected by the AT domains. These domains thus govern to a large extent the branching functionality within polyketide structures. Correspondingly, manipulation of AT domains using genetic engineering offers a powerful potential means for the regioselective diversification of polyketide skeletons, especially in the case of ATs which exhibit unusual substrate specificity relative to the typical choice of malonyl-CoA or methylmalonyl-CoA 1 (e.g. for propyl-, butyl-, allyl-malonyl-CoA, etc. 2 - 4 ). To date, a variety of approaches including AT domain exchange, in trans AT complementation, and active site-directed mutagenesis have been applied to polyketide structural engineering with varying levels of success 5 . Experimentally, AT swapping consists of exchanging only the AT domain within a module of interest for an AT of different substrate specificity from another module, either sourced from the same or a different PKS 6 - 10 . This approach has resulted in various hybrid metabolites, with recent work revealing highly effective domain boundaries for such exchanges 11 , 12 . Concerning the complementation strategy, it involves selectively inactivating the native AT within a particular PKS module and rescuing its activity via a co-expressed trans -acting AT 4 , 13 , 14 . Drawbacks of this approach include that it depends on the ability of the trans- ATs to recognize noncognate ACPs as partners 14 , and the typically limited substrate (for malonate) 4 of these enzymes. Finally, AT active site mutagenesis has been used in efforts to redirect and/or broaden innate AT substrate selectivity 15 - 17 . Despite the availability of several AT crystal structures 18 - 21 , this approach remains hampered by the paucity of co-complex structures in the presence of native extender units. Indeed, all such attempts to date to switch AT specificity have only resulted in a shift in substrate preference 4 , 15 - 17 , 22 , a result potentially explained by the currently insufficient predictive power of the identified AT substrate-binding motifs 12 . An alternative approach towards polyketide structural diversification is to exploit the intrinsically broad substrate specificity of certain ATs, and challenge them with alternative building blocks via precursor-directed biosynthesis (PDB) and/or mutasynthesis 23 - 31 . In the case of PDB ( Figure 1a ), the supplied ‘mutasynthons’ must compete with the native substrates, while in a mutasynthetic strategy ( Figure 1b ), precursor biosynthesis is disabled 2 , and thus the pathway depends, at least in principle, on the presence of the exogenous building block in order to function. To date, multiple functional groups including several not found naturally in polyketides have been incorporated into polyketides in this manner, including alkyne, azide, and halogen moieties 24 - 31 . Download figure Open in new tab Figure 1. Schematic overview of the (a) Precursor-directed biosynthesis (PDB) and (b) mutasynthesis approaches 23 , and the (c) mutasynthesis strategy applied to stambomycin biosynthesis. Commercially sourced and synthetic malonic acids incorporating a wide variety of side chains were fed to the production culture of mutasynthesis mutant ATCC/OE484/Δ483. At least six of these alternative extender units were then successfully activated to their corresponding CoAs by the promiscuous MatB_Sa of S. ambofaciens , and incorporated into the pathway by AT 12 , resulting in stambomycin derivatives bearing modifications at C-26, a position which directly impacts the bioactivity 42 . The hydroxylation at C-28 (red circle) was found to occur to variable extents, but the hydroxylation at C-50 and mycaminosylation went to completion. Evidently, a critical parameter for successful PDB and/or mutasynthesis is exogenous precursor supply. Previous in vitro studies have shown that commercially available malonyl-CoA derivatives can be used as mutasynthons 32 . However, this method is not suitable for in vivo feeding studies due to poor acyl-CoA membrane permeability 33 . This problem can be addressed by the use of synthetic N -acetylcysteamine thioesters (SNACs) which mimic the distal end of CoA, but leveraging them in large-scale applications is complicated by the need to synthesize the compounds, as well as their cellular toxicity 34 . A promising alternative is a chemoenzymatic approach, in which a fed monomer (mono-or di-acid) is activated to its corresponding malonyl- CoA derivative in cellulo by an appropriate enzyme − either a crotonyl-CoA reductase/carboxylase (CCR) 35 - 38 homologue or a broad-specificity malonyl-CoA synthetase (MatB) 18 , 34 , 39 - 41 homologue ( Figure S1a, b ). ATs which recognize atypical extender units typically show broad substrate specificity relative to their malonate-or methylmalonate equivalents 12 , 38 . Even among such domains, a particularly promiscuous AT participates in the biosynthesis of the stambomycin family of 51-membered macrolides in S. ambofaciens ATCC23877 42 - 44 . This domain (AT 12 ) naturally recruits at least six atypical alkyl malonyl-CoA-derived extender units: (4-methylhexyl)malonyl-CoA, (5-methylhexyl)malonyl-CoA, (4-methylpentyl)malonyl-CoA, n -hexylmalonyl-CoA, n -pentylmalonyl-CoA and (4,5-dimethylhexyl)malonyl-CoA ( Figure 1c ). This broad specificity results in six stambomycins (A−F, respectively) bearing distinct side chains at C-26. Notably, modifications at this position directly impact the biological properties of the metabolites, with stambomycins C/D showing improved antiproliferative activity towards a range of human cancer cells 42 . In contrast to the typical CCR-mediated synthesis of polyketide extender units via reductive carboxylation of α,β-unsaturated acyl-thioesters 35 - 38 , the stambomycin precursors are generated by direct carboxylation of medium chain acyl-CoA substrates catalyzed by the ATP-dependent enzyme SamR0483 (although SamR0483 was renamed MccB for medium chain acyl-CoA carboxylase β-subunit, we will refer to it here as SamR0483 in line with the gene nomenclature) 44 ( Figure S1c ). The acyl-CoAs derive either from the corresponding amino acids via the consecutive action of the branched-chain α-keto acid dehydrogenase complex and primary metabolic fatty acid synthase enzymes (FabH and FabF), or via direct conversion of the corresponding fatty acids to their CoA thioesters by SamR0482, a medium chain fatty acyl-CoA ligase homologue 44 . Notably, SamR0482 and SamR0483 together were shown to generate the corresponding extender units from 6-azidohexanoic acid and 8-nonyoic acid, resulting in stambomycin C-26 analogues bearing azide and alkyne groups. Thus, in addition to the intrinsically broad specificity of AT 12 and all twelve downstream PKS modules, Sam0482 and SamR0483 exhibit useful substrate tolerance. Here we aimed to further exploit the intrinsic flexibility of the stambomycin pathway to access a larger panel of analogues by mutasynthesis for biological testing ( Figure 1c ). For this, we first disrupted the supply of the native extender units by mutational inactivation of samR0483 . We then fed the resulting strains with 12 commercially-available or synthetic malonic acid derivatives, relying either on the intrinsic promiscuity of the S. ambofaciens MatB (MatB_Sa) or heterologously-expressed MatB from S. cinnamonensis 45 for activation to their respective CoA thioesters. Six of the derivatives resulted in stambomycin analogues incorporating or lacking hydroxylation at C-28, including four at yields sufficient for structure elucidation by NMR and for biological activity tests. We further show that MatB_cinna is more effective than the native S. ambofaciens homologue at monomer activation, while direct comparison of the yields obtained by PDB and mutasynthesis confirms the relative utility of the latter approach for analogue generation. Results Construction of a mutant for stambomycin mutasynthesis In order to disable the native pathway to the six extender units, the genes encoding SamR0482 and SamR0483 were deleted using PCR-targeting, resulting in the mutants ATCC/Δ482 46 and ATCC/Δ483 ( Tables S1 − S4 ). Subsequently, the LAL regulator overexpressing plasmid pOE484 was introduced into the mutants as previously described to trigger stambomycin biosynthesis 42 , affording the mutants ATCC/OE484/Δ482 46 and ATCC/OE484/Δ483 ( Table S1 ). Extracts of mutants ATCC/OE484/Δ482 and ATCC/OE484/Δ483 were then analyzed by LC-HRMS in comparison to the control strain ATCC/OE484. This analysis revealed that while production by ATCC/OE484/Δ483 was almost completely abolished ( Figure 2 ), the ATCC/OE484/Δ482 mutant continued to produce stambomycins at approximately 51% yield relative to the wild type strain ( Figure 2 ). BlastP analysis 47 of the S. ambofaciens genome using SamR0482 as a query revealed several homologues, two of which are located in the antimycin and congocidine clusters: AntF (acyl-CoA synthetase, 29.8% amino acid identity to SamR0482) and Cgc22 (acyl-CoA synthetase, 34.5% amino acid identity to SamR0482). We thus propose that in addition to provision of the necessary acyl-CoAs via core metabolism, the loss-of-function of SamR0482 may be compensated by either AntF, Cgc22 or both ( Table S1 ). BlastP analysis using SamR0483 also revealed several homologues, notably including the duplicated enzyme AlpX (proposed to be involved in kinamycin biosynthesis 48 , 49 ) and two propionyl-CoA carboxylase (PCC) β-subunits which show 59% and 52% amino acid identity to SamR0483 and high mutual similarity ( Table S1 ). However, PccBs typically act on short chain acyl-CoAs 50 , potentially explaining why only a low level of SamR0483 complementation was observed (0.3% stambomycin yield relative to wild type). Download figure Open in new tab Figure 2. Analysis by (a) mass spectrometry and (b) UV at λ max 238 nm of ATCC/OE484 (control) and mutants for mutasynthesis. The TIC (total ion chromatogram) and UV spectrum of ATCC/OE484/Δ483 clearly show that production by the mutant of the stambomycins (peaks highlighted in grey) is almost abolished. The indicated yields of stambomycins (AB and CD) in the wild type and mutant strains are based on integration of the EIC (extracted ion chromatogram) peaks and a previously generated standard curve for stambomycin AB 43 . The calculated areas represent the average of the analysis of at least two independent clones of each strain. To confirm that the substantial decrease in stambomycin production in the ATCC/OE484/Δ483 mutant was due to the loss function of SamR0483, we carried out a complementation experiment by integrating the samR0483 gene into the genome of ATCC/OE484/Δ483 mutant under the control of the constitutive promoter ermEp * 51 . Although the observed complementation was incomplete (31% stambomycin yields relative to wt ( Figure 2 )), restoration of biosynthesis nonetheless supports the proposed essential role for SamR0483 in the pathway 44 . We therefore used mutant ATCC/OE484/Δ483 as our base strain for the mutasynthesis experiments ( Figure 2 ). Mutasynthesis of stambomycin analogues BlastP analysis against the genome sequence of S. ambofaciens using the MatB_Sc ( S. coelicolor ) 40 as the query revealed an enzyme (referred to here as MatB_Sa) with amino acid identity of 90% to MatB_Sc. Sequence alignment also showed that MatB_Sa shares 75% and 39% amino acid identity with MatB_cinna ( S. cinnamonesis ) 34 and MatB_Rt ( Rhizobium trifolii ) 41 , respectively ( Figure S2 ). The high homology between MatB_Sa and the demonstrably promiscuous MatB_cinna 34 suggested that MatB_Sa might also possess the necessary broad specificity to efficiently activate non-native malonate derivatives to their corresponding CoAs. On this basis, individual cultures of the ATCC/OE484/Δ483 mutant strain were supplemented with a wide panel of commercially sourced and synthetic diacids, including ethyl-, isopropyl-, allyl-, butyl-, benzyl-, octyl-, phenylpropyl-, phenoxypropyl-, thiophene-, thienylmethyl-, propargyl-, and 6-bromohexyl-malonic acids ( Figure 1c ) at a final concentration of 10 mM, in parallel with a control ( i . e . a culture of the mutant strain lacking added malonic acid derivatives). Analysis of cell pellets following extraction with methanol by LC-HRMS showed that the supplementation with ethyl-(giving rise to compound 1 ), allyl-( 2 and 3 ), butyl-( 4 and 5 ), benzyl-( 6 and 7 ), phenoxypropyl-( 9 and 10 ), and 6-bromohexyl-malonic acids ( 11 ) yielded new peaks relative to the control, all with masses consistent with the expected C26-modified stambomycin analogues ( Table 1 and Figure S3a, c, d, e, h, l ). It must nonetheless be noted that the exact mass of the 6-bromohexyl-malonic acid analogue corresponds to a structure lacking two of the expected hydrogens ( Figure S3l ). This structural variation may correspond to a ketone at position C-28 instead of the expected hydroxyl functionality, due to over-oxidation by the P450 hydroxylase SamR0478 52 . Indeed, SamR0478 belongs to the CYP107H family whose members have been shown to catalyse ketonization of C-H bonds, but this hypothesis remains to be verified). In contrast, the phenylpropyl-, thiophene-, thienylmethyl-, and propargyl-malonic acids failed to be incorporated ( Table 1 , Figure S3b, g, i, j, k and Tables S5−S7 ). A peak at 1390.9546 ([M+H] + , C 74 H 130 NO 22 + ; r.t. 25.4 min) found in the octyl-fed extract ( Table 1 ) requires further investigation, in order to determine whether it corresponds to a novel octyl-stambomycin ( 8 ) or the native stambomycin F 53 (r.t. 24.2 min), as the two masses are identical ( Table S5 ). Arguing for the formation of octyl-stambomycin, however, the observed yield of the metabolite is 9.2% relative to the stambomycins A−D ( Figure S3f ), while the typical titers of stambomycin F are only 2.5% ( Figure S4a ). View this table: View inline View popup Download powerpoint Table 1. Production of stambomycins and stambomycin analogues (the observed compounds are numbered) resulting from mutasynthesis strain ATCC/OE484/Δ483 in the presence of supplemental malonic acid derivatives (final concentration of 10 mM). The amount of stambomycins (A–D) produced by ATCC/OE484/Δ483 in the absence of supplementation was set to 100%. For details, see Figure S3 . Biosynthesis of the parental stambomycins involves C-28 hydroxylation by the P450 hydroxylase SamR0478, as well as on-line C-50 hydroxylation by a second P450 SamR0479 to generate the nucleophile required for macrolide formation 54 . For five of the successfully incorporated precursors (ethyl-, allyl-, butyl-, benzyl- and phenoxypropyl-malonate), the macrocyclic stambomycin analogues lacking C-28 hydroxylation (the ‘deoxy’ forms, 1, 3 , 5, 7 and 10 ) were the main or even sole products ( i . e . no ethyl-stambomycin was detected), accounting for 55.3−99.5% of the total yields based on their relative abundance in the mass spectra. In contrast, 6-bromohexyl-stambomycin ( 11 ) is the sole analogue observed in the 6-bromohexyl feeding experiments. This observation suggests that SamR0478 strongly prefers its native substrates or at minimum closely similar chains ( Figure 1 ). In contrast, in no case were aglycone analogues detected in the fed extracts (data no shown), showing that the post-PKS glycosylase SamR0481, exhibits broad substrate tolerance, at least towards substrates of comparable size to the parental stambomycins 43 ( Figure 1 ). Unexpectedly, for all fed extracts with the exception of thiophene-malonic acid and thienylmethyl-malonic acid for which there was no change, peaks corresponding to stambomycins A/B and C/D were always present, and at yields 2−8 times higher than from the unsupplemented ATCC/OE484/Δ483 mutasynthesis mutant ( Table 1 and Figure S3 ). To explain this surprising observation, we propose that the fed malonic acid derivatives somehow induce expression of the identified SamR0483 homologues ( Table S1 ), which can then more substantially compensate for the loss of SamR0483. However, this mechanism remains to be verified directly by targeted inactivation. Quantitative analysis of the stambomycin derivatives produced by the mutasynthesis mutants ATCC/OE484/Δ483 and ATCC/OE484/Δ483/MatB_cinna We next considered whether the lack of production of stambomycin derivatives in the presence of isopropyl-, phenylpropyl-, thiophene-, thienylmethyl-, and propargyl-malonic acid, might have resulted from intolerance to the modified polyketide chains by modules downstream of AT 12 . As such a mechanism could have resulted in release of stalled intermediates, we analyzed the extracts for the presence of intermediates corresponding to the products of modules 12 and 13. However, no convincing signal was detected (data not shown). Furthermore, we did not detect any of these predicted shunt products in extracts from feeding experiments where the stambomycin analogues were obtained, consistent with the idea that the modules downstream of module 12 are broadly tolerant to alternative chains. In light of this evidence, we hypothesized that the major blocks to incorporation of diacids were failure to efficiently activate the fed substrates to their CoA forms by MatB_Sa, or the inability of AT 12 to recognize the modified malonates. To directly address the first possibility, we introduced promiscuous MatB_cinna 45 into mutant ATCC/OE484/Δ483, resulting in mutant ATCC/OE484/Δ483/MatB_cinna. Mutants ATCC/OE484/Δ483 and ATCC/OE484/Δ483/MatB_cinna were then fed with ethyl-, allyl-, butyl- and benzyl-malonic acids, followed by quantification of the resulting analogues produced by the two strains. For this, erythromycin (1 mM added during the work-up step) was used as an internal standard for the LC-HRMS analyses to control for any differences in extraction efficiency. The obtained data demonstrated that the presence of MatB_cinna improved the incorporation of ethyl-, allyl- and benzyl-malonic acids ( Figure 3a, b, d ), resulting in a nearly 2-fold increase relative to the parental strain which contains only MatB_Sa. Indeed, recent work has demonstrated that MatB_cinna efficiently converts ethyl-, allyl- and benzyl-malonic acid to their corresponding CoA forms 34 , which is consistent with the results obtained here. In contrast, levels of incorporation of butyl-malonic acid by the two mutants was essentially identical (88% vs 71%, Figure 3c ), reflecting the fact that MatB_cinna is poorly active with butyl-diacid 34 . Download figure Open in new tab Figure 3. Quantitative analysis of the mutasynthesis mutants ATCC/OE484/Δ483 and ATCC/OE484/Δ483/ MatB_cinna by LC-HRMS using erythromycin as the internal standard. a) Comparison of the two mutants when supplied with ethylmalonic acid. b–d) Analysis following supplementation with allyl-, butyl- and benzylmalonic acids. TIC (total ion chromatogram) of the crude extract is shown in the top panel in each case. The amount of stambomycins (A–D) and stambomycins analogues relative to the internal standard erythromycin A were determined using the integrated area of EIC peaks (mean value of three individual fermentation results), with the peak area of the standard set to 100%. With the aim of obtaining definitive structural proof for certain analogues, we therefore used ATCC/OE484/Δ483/ MatB_cinna to obtain allyl-incorporated stambomycin, and the original mutant ATCC/OE484/Δ483 to produce the butyl variant. This approach resulted in sufficient quantities of deoxy-allyl-stambomycin ( 3 ) (0.7 mg/L) to allow for its purification (the yields of allyl-stambomycin ( 2 ) were inadequate), while three compounds (22.5 mg/L combined yield of the two most abundant compounds) were purified from extracts of ATCC/OE484/Δ483 fed with butyl-malonic acid. The structures of these four compounds were elucidated by comprehensive NMR and HRMS analysis ( Figure S5 – S29 ), yielding data consistent with deoxy-allyl-stambomycin ( 3 ), deoxy-butyl-stambomycin ( 5 ) and butyl-stambomycin ( 4 ). Concerning the third butyl derivative, comparison of the obtained NMR data with that of butyl-stambomycin ( 4 ) revealed a methyl signal missing from the 1 H NMR spectrum (δ H 1.64) corresponding to the methyl at C-24, and the shift of an olefinic proton from δ H 5.22 to δ H 5.43. Additionally, coupling constants of 15.4 and 8.0 were observed for H-25 ( Figures S17 – 22 ). These data are all consistent with a C-24-demethyl derivative of butyl stambomycin ( 12 ). Such a compound would arise from alternative incorporation of malonyl-CoA instead of methymalonyl-CoA by AT 13 , a reasonable hypothesis given the intrinsically broad specificity of AT 12 . In support of this hypothesis, reinspection of wild type extracts revealed a peak with a mass of 1334.8911 (C 70 H 128 NO 22 + ; m / z [M+H] + = 1334.8922, Δppm = −0.8), which matches that of a demethyl derivative of stambomycin E ( Figure S4b ) (note, it was not possible to conclusively identify analogous demethyl analogues of stambomycins AB, CD and F, as C-24-demethyl-stambomycins AB would have the same exact masses as stambomycins CD, C-24-demethyl-stambomycins CD, the same masses as stambomycin E, and C-24-demethyl-stambomycin F the same as stambomycins AB). Quantitative comparative analysis of the PDB and mutasynthesis approaches As we observed production of the parental stambomycins in the mutasynthesis strains which is the classical outcome of PDB experiments, it was of interest to directly compare the relative efficiency of mutasynthesis to PDB. In contrast to mutasynthesis, PDB in S. ambofaciens relies on fed mono-acids, which are then activated by the SamR0482/SamR0483 pair to generate the corresponding extender unit CoA thioesters. Thus, to judge the relative efficacies of the two approaches, we supplemented strain ATCC/OE484 with 3-butenoic acid, butyric acid and phenyl propanoic acid ( Figure 4a ), and in parallel, mutant ATCC/OE484/Δ483 with the corresponding allyl-, butyl- and benzyl-malonic acids ( Figure 4b ). Erythromycin (1 mM) was again used as internal standard in the LC-HRMS analyses to permit accurate quantification. The obtained data showed that butyric acid was activated by the SamR0482/SamR0483-mediated pathway in strain ATCC/OE484, resulting in butyl-incorporated stambomycin analogues ( Figure 4d ), but that incorporation of 3-butenoic acid and benzyl-malonic acid failed ( Figure 4c, e ). Moreover, the yield of butyl-incorporated analogues from mutasynthesis with the ATCC/OE484/Δ483 strain relative to PDB based on ATCC/OE484 (88% vs 11%, Figure 4d ), confirmed that mutasynthesis was the superior approach, despite the continued biosynthesis of the wild type stambomycins. Download figure Open in new tab Figure 4. Quantitative analysis of PDB and mutasynthesis-mediated biosynthesis of stambomycin analogues. a) PDB: the culture medium is supplemented with monoacids, which are converted to extender units for AT 12 by the two-enzyme pathway involving SamR0482 and SamR0483. b) Mutasynthesis: the culture medium is supplemented with diacids, which are converted to acyl-CoA extender units for AT 12 by MatB_Sa. c−e) Quantitative analysis of crude extracts of the PDB and mutasynthesis experiments. The amount of stambomycins (A–D) and stambomycin analogues relative to the internal standard (erythromycin A) were determined via the integrated area of the EIC peaks (mean value of three individual fermentation results), with the peak area of the standard set to 100%. Biological activities of the stambomycin analogues The stambomycins have moderate activity against Gram-positive bacteria but none against Gram-negative bacteria 42 . More interestingly they were also shown to possess antiproliferative activity towards a range of human cancer cells, with potency comparable to several clinically-used compounds 42 . We therefore tested the bioactivity of the four purified stambomycin analogues ( 3, 4, 5 and 12 ). All four exhibited anti-bacterial activity, albeit variable, against both Gram-positive Bacillus subtilis and Micrococcus luteus , but not against the Gram-native Escherichia coli ( Figure S30 ). The butyl- and deoxy-butyl-stambomycins ( 4 and 5 ) were the most active (with an efficiency similar to the original stambomycins), while the allyl form ( 3 ) showed only weak activity. Interestingly, the C-24-demethyl derivative of butyl-stambomycin ( 12 ) was less active relative to the (deoxy-)butyl-stambomycins. Next, we tested the antiproliferative activities against two human cancer cell lines, U87-MG glioblastoma cells (brain cancer) and MDA-MTB-231 cells, which are commonly used to model late-stage breast cancer. MTT assays revealed significant and similar antiproliferative activities against the two lines for the butyl-stambomycin and its deoxy form ( Figure S31 ) with IC 50 values around 1 μM for both the U87 and the MDA-MB-231 cells ( Table S9 ). These values are in the range of those observed for the parental stambomycins 42 and are better than those observed for the clinical anticancer agent doxorubicin used as a control ( Table S9 ). Cell counting further confirmed that the inhibition observed in the MTT assays was related to cell death ( Figure S31 ). As observed with the anti-bacterial assays, the C-24-demethyl derivative ( 12 ) of butyl-stambomycin and the allyl analogue ( 3 ) were significantly less active against the two cell lines ( Table S9, Figure S31 ). Discussion and Conclusions In contrast to many PKS AT domains which exhibit strict substrate specificity 4 , the AT 12 domain of the stambomycin biosynthetic pathway naturally recognizes at least six atypical malonate extender units, attesting to its innate broad substrate tolerance. This promiscuity in fact extends to all 12 downstream PKS modules and post-PKS enzymes, as the system generates a family of fully-elaborated stambomycins 42 . These observations motivated us to try to expand the library of available stambomycin C26 analogues 44 for biological evaluation using a mutasynthesis approach. For this, we aimed to disable production of the native extender units by targeting the enzymes (SamR0482 and SamR0483) involved in their biosynthesis from medium-chain fatty acids 44 . By deletion of the individual genes, we demonstrated that SamR0483 was critical for stambomycin biosynthesis in the absence of additional growth modification, but that SamR0482 could be complemented by other enzymes encoded in the genome. We therefore carried out mutasynthesis using the SamR0483 inactivation mutant. Supplementation of ATCC/OE484/Δ483 with suitable precursors yielded 6 novel series of stambomycin analogues at varying yields. Derivatives obtained in this way incorporated ethyl, butyl, allyl, benzyl, phenoxypropyl and 6-bromohexyl groups at C-26 instead of the native chains ( Table 1 ) (initial evidence was also obtained for the C-26 octyl analogue). For each of the analogues except that bearing the 6-bromohexyl group which was fully modified, a major proportion of the compounds lacked the C-28 hydroxylation catalyzed by the P450 enzyme SamR0478. It is also notable that feeding of butylmalonic acid resulted in almost exclusive production of butyl-stambomycin relative to residual stambomycins A−D, whereas the native metabolites dominated in previous precursor-directed biosynthesis experiments 44 . Indeed, in our hands, the PDB approach only yielded a single novel derivative when a limited series of monoacid substrates was fed. Overall, successful production of this panel of analogues depended on the intrinsic substrate tolerance of three distinct enzymatic events in the pathway: the MatB_Sa-catalyzed activation of the diacids as their CoA thioesters, substrate selection and ACP loading by AT 12 , and recognition of the modified intermediates by the downstream PKS modules, the C-50 hydroxylase SamR0479 54 , and SamR0481-mediated mycaminosylation. It is also worth noting that producing comparable analogues using synthetic chemistry would require their total synthesis. Nonetheless, the intrinsically broad specificity of AT 12 and the overall PKS system did not translate into universal acceptance of all alternative building blocks. Intriguingly, despite the bulky nature of the (methyl)pentyl/(methyl)hexyl side chains of the native extender units, the non-native analogues showing the highest level of incorporation were significantly shorter ( i . e . butyl and allyl). The efficient incorporation of butyl-malonic acid is also notable for a second reason, as it suggests that MatB_Sa has unusually high activity towards this substrate, which was not seen with MatB_cinna 34 and MatB_Rt 41 despite their intrinsic promiscuity. This hypothesis is also supported by the fact that expression of MatB_cinna alongside MatB_Sa did not improve incorporation of butyl-malonate by the strain. Concerning the substrates which were not accepted (isopropyl, phenylpropyl-, thiophene-, thienylmethyl- and propargylmalonic acid), it is not possible to conclusively identify the enzymatic bottleneck(s), as none of these substrates were directly evaluated in previous work with MatB_cinna 34 , but the absence of prematurely released chain extension intermediates points to either AT 12 or MatB. Our positive incorporation results notably contrast with recent data obtained from an engineered swap of AT 12 into module 6 of the erythromycin (DEBS) PKS 12 . In this case, analysis in vitro with purified hybrid protein and a series of α-carboxyacyl-CoA substrates revealed essentially no activity towards ethyl- and allylmalonyl-CoA, comparable but low activity with propyl-, butyl-, pentyl-, hexylmalonyl-CoA, and a pronounced preference for isopentyl-CoA. This result taken alongside other obtained data was interpreted to show that atypical AT domains can incorporate extender units which are equal in size or slightly larger than their native substrates 12 . Indeed, AT 12 was predicted by AlphaFold2 12 , 55 to possess one of the largest active site cavity volumes among the evaluated ATs, in accord with the high steric demands of its native substrates. At this stage it is difficult to reconcile the two sets of data, particularly as incorporation of butyl-malonyl-CoA in our hands resulted in mature analogues at yields comparable to that of the parental stambomycins (20–30 mg/L) 42 . Either the AT in its native context exhibits a more relaxed specificity, or the specificity of AT 12 was unchanged, but the tolerance of the other DEBS module 6 domains was negatively impacted by introduction of this heterologous AT (in the presence of alternative non-native ATs, DEBS module 6 accepted both allyl- and butylmalonyl-CoA with good efficiency 12 ). Another possible explanation, however, is that insertion of AT 12 into the module caused structural perturbation, which impacted turnover. Indeed, the AT swapped modules which gave the lowest purification yields relative to wild type also exhibited the most restricted substrate specificities 12 . In any case, the cumulative results point to a complex interplay between the AT and the remaining domains of the PKS in determining the efficacy with which alternative building blocks can be incorporated into engineered polyketides. Our observation that the butyl (C 4 ) congeners ( 4 and 5 ) retained good activity relative to the native metabolites (linear and branched C 5 and C 6 side chains) demonstrates a certain tolerance to the chain length and functionality at the C-26 position. However, the allyl analogue (C 3 ) ( 3 ) was markedly less potent, an effect which may be due to the further reduced length, or the presence of the double bond. Our data also confirm an earlier observation made with the parental stambomycins 46 that the hydroxylation at C-28 has no significant effect on the biological activities of the analogues. Interestingly, the methyl group at C-24 appears to contribute significantly to both the antibacterial and antiproliferative properties of the derivatives, as its absence ( i . e . 12 ) results in a sharp decrease in bioactivity. Potential reasons for this drop include reduced lipophilicity and thus biomembrane solubility, or the lack of an important conformational constraint on the macrolides. We note that the effect of methylation on biological interactions has strong precedence in the literature 56 . Finally, given the observed specificity differences between MatB_Sa and MatB_cinna, it would be of interest to attempt to further broaden the substrate tolerance of MatB_Sa by structure-guided mutagenesis. Notably, an engineered version of MatB_Rt (T207G/M306I) showed improved catalytic activity toward ethyl-, propargyl- and allyl-malonic acids, as well some tolerance towards isopropyl-, butyl-, phenyl-, and azido-malonic acids 41 . The two residues corresponding to T207 and M306 in MatB_Sa are V190 and M293 ( Figure S3 ), which could be modified in attempts to similarly broaden the substrate scope of MatB_Sa. In parallel, it would be worth targeting for inactivation the identified homologues of SamR0483 in order to reduce the background synthesis of the parental stambomycins, potentially boosting the yields of the novel derivatives. We also envision that an analogous mutasynthesis strategy could be applied to other-diversity oriented pathways but with supplementation using one of the native precursors – redirecting the pathway to production of a single natural compound which should simplify purification and subsequent structure elucidation 57 . Together, such approaches should further expand the enzymatic toolbox available for efficient AT-based polyketide analogue generation. Author contributions K. J. W. and B. A. designed and supervised the project, with initial assistance from C.J. K. J. W. and B. A. obtained the funding at the U.L. and H.B.B. at the MPI. L. S. constructed and fermented (together with L. H., Y. S., and C. J.) the mutasynthesis strains, and analysed and interpreted the LC-MS data. Y. S. synthesized propargyl-malonic acid and interpreted the NMR data. P. G., Y-N. S., and H. B. B purified compounds and performed the NMR measurements. A. C. and S. P. carried out the biological testing. L. S., B. A. and K. J. W. wrote the manuscript, with contributions from all authors. Conflicts of interest There are no conflicts to declare. Acknowledgements We acknowledge financial support from the Université de Lorraine, the Centre National de la Recherche Scientifique (CNRS), and the IMPACT Biomolecules project of the Lorraine Université d’Excellence (LUE) (Investissements d’avenir − ANR 15-004 to L.S., Y.S., C.J., B.A., and K.J.W.). Work in the Bode lab was supported by an ERC Advanced Grant (835108) and the Max-Planck-Society. We are grateful to Prof. Yi Yu (Wuhan University, China) for the chemical synthesis of 6-bromohexyl-malonic acid and Prof. Frank Schulz (Ruhr-Universität Bochum, Germany) for the plasmid encoding MatB_cinna. We are grateful for access to the PASM platform of the Université de Lorraine, and the technical assistance provided by C. Paris. References 1. ↵ C. A. Dejong , G. M. Chen , H. Li , C. W. Johnston , M. R. Edwards , P. N. Rees , M. A. Skinnider , A. L. Webster and N. A. Magarvey , Nat Chem Biol , 2016 , 12 , 1007 – 1014 . OpenUrl CrossRef PubMed 2. ↵ S. Mo , D. H. Kim , J. H. Lee , J. W. Park , D. B. Basnet , Y. H. Ban , Y. J. Yoo , S. W. Chen , S. R. Park , E. A. Choi , E. Kim , Y. Y. Jin , S. K. Lee , J. Y. Park , Y. Liu , M. O. Lee , K. S. Lee , S. J. Kim , D. Kim , B. C. Park , S. G. Lee , H. J. Kwon , J. W. Suh , B. S. Moore , S. K. Lim and Y. J. Yoon , J Am Chem Soc , 2011 , 133 , 976 – 985 . OpenUrl CrossRef PubMed Web of Science 3. M. Sandy , Z. Rui , J. Gallagher and W. Zhang , ACS Chem Biol , 2012 , 7 , 1956 – 1961 . OpenUrl CrossRef PubMed 4. ↵ B. J. Dunn and C. Khosla , J R Soc Interface , 2013 , 10 , 20130297 . OpenUrl CrossRef PubMed 5. ↵ K. J. Weissman , Natural Product Reports , 2016 , 33 , 203 – 230 . OpenUrl CrossRef PubMed 6. ↵ L. Liu , A. Thamchaipenet , H. Fu , M. Betlach and G. Ashley , Journal of the American Chemical Society , 1997 , 119 , 10553 – 10554 . OpenUrl CrossRef 7. X. Ruan , A. Pereda , D. L. Stassi , D. Zeidner , R. G. Summers , M. Jackson , A. Shivakumar , S. Kakavas , M. J. Staver , S. Donadio and L. Katz , Journal of Bacteriology , 1997 , 179 , 6416 . OpenUrl Abstract / FREE Full Text 8. D. L. Stassi , S. J. Kakavas , K. A. Reynolds , G. Gunawardana , S. Swanson , D. Zeidner , M. Jackson , H. Liu , A. Buko and L. Katz , Proceedings of the National Academy of Sciences , 1998 , 95 , 7305 . OpenUrl Abstract / FREE Full Text 9. R. McDaniel , A. Thamchaipenet , C. Gustafsson , H. Fu , M. Betlach , M. Betlach and G. Ashley , Proceedings of the National Academy of Sciences , 1999 , 96 , 1846 . OpenUrl Abstract / FREE Full Text 10. ↵ H. Petkovic , R. E. Lill , R. M. Sheridan , B. Wilkinson , E. L. McCormick , H. A. I. McArthur , J. Staunton , P. F. Leadlay and S. G. Kendrew , Journal of Antibiotics , 2003 , 56 , 543 – 551 . OpenUrl CrossRef PubMed 11. ↵ S. Yuzawa , K. Deng , G. Wang , E. E. K. Baidoo , T. R. Northen , P. D. Adams , L. Katz and J. D. Keasling , Acs Synthetic Biology , 2017 , 6 , 139 – 147 . OpenUrl CrossRef PubMed 12. ↵ E. Englund , M. Schmidt , A. A. Nava , A. Lechner , K. Deng , R. Jocic , Y. Lin , J. Roberts , V. T. Benites , R. Kakumanu , J. W. Gin , Y. Chen , Y. Liu , C. J. Petzold , E. E. K. Baidoo , T. R. Northen , P. D. Adams , L. Katz , S. Yuzawa and J. D. Keasling , J Am Chem Soc , 2023 , 145 , 8822 – 8832 . OpenUrl CrossRef PubMed 13. ↵ B. J. Dunn , K. R. Watts , T. Robbins , D. E. Cane and C. Khosla , Biochemistry , 2014 , 53 , 3796 – 3806 . OpenUrl CrossRef PubMed 14. ↵ M. Hans , A. Hornung , A. Dziarnowski , D. E. Cane and C. Khosla , J Am Chem Soc , 2003 , 125 , 5366 – 5374 . OpenUrl CrossRef PubMed Web of Science 15. ↵ U. Sundermann , K. Bravo-Rodriguez , S. Klopries , S. Kushnir , H. Gomez , E. Sanchez-Garcia and F. Schulz , ACS Chemical Biology , 2013 , 8 , 443 – 450 . OpenUrl CrossRef PubMed 16. K. Bravo-Rodriguez , S. Klopries , K. R. M. Koopmans , U. Sundermann , S. Yahiaoui , J. Arens , S. Kushnir , F. Schulz and E. Sanchez-Garcia , Chem Biol , 2015 , 22 , 1425 – 1430 . OpenUrl CrossRef PubMed 17. ↵ I. Koryakina , C. Kasey , J. B. McArthur , A. N. Lowell , J. A. Chemler , S. Li , D. A. Hansen , D. H. Sherman and G. J. Williams , ACS chemical biology , 2017 , 12 , 114 – 123 . OpenUrl CrossRef PubMed 18. ↵ Y. Li , W. Zhang , H. Zhang , W. Tian , L. Wu , S. Wang , M. Zheng , J. Zhang , C. Sun , Z. Deng , Y. Sun , X. Qu and J. Zhou , Angew Chem Int Ed Engl , 2018 , 57 , 5823 – 5827 . OpenUrl CrossRef PubMed 19. F. Zhang , T. Shi , H. Ji , I. Ali , S. Huang , Z. Deng , Q. Min , L. Bai , Y. Zhao and J. Zheng , Biochemistry , 2019 , 58 , 2978 – 2986 . OpenUrl CrossRef PubMed 20. C. Khosla , Y. Tang , A. Y. Chen , N. A. Schnarr and D. E. Cane , Annu Rev Biochem , 2007 , 76 , 195 – 221 . OpenUrl CrossRef PubMed Web of Science 21. ↵ P. Paiva , S. F. Sousa , M. J. Ramos and P. A. Fernandes , ACS Catalysis , 2018 , 8 , 4860 – 4872 . OpenUrl CrossRef 22. ↵ E. E. Drufva , E. G. Hix and C. B. Bailey , Synth Syst Biotechnol , 2020 , 5 , 62 – 80 . OpenUrl CrossRef PubMed 23. ↵ K. J. Weissman , Trends Biotechnol , 2007 , 25 , 139 – 142 . OpenUrl CrossRef PubMed Web of Science 24. ↵ R. J. M. Goss , S. E. Lanceron , N. J. Wise and S. J. Moss , Organic & Biomolecular Chemistry , 2006 , 4 , 4071 – 4073 . OpenUrl CrossRef PubMed 25. R. J. M. Goss , S. Lanceron , A. Deb Roy , S. Sprague , M. Nur-e-Alam , D. L. Hughes , B. Wilkinson and S. J. Moss , ChemBioChem , 2010 , 11 , 698 – 702 . OpenUrl CrossRef PubMed Web of Science 26. Y. H. Ban , J. H. Lee , G. R. Gu , B. Lee , S. Mo , H. J. Kwon and Y. J. Yoon , Molecular BioSystems , 2013 , 9 , 944 – 947 . OpenUrl CrossRef PubMed 27. D. H. Kim , J. H. Ryu , K. S. Lee , B. M. Lee , M. O. Lee , S.-K. Lim and P. J. Maeng , Applied Microbiology and Biotechnology , 2013 , 97 , 5881 – 5892 . OpenUrl CrossRef 28. O. Ghisalba , H. Fuhrer , W. J. Richter and S. Moss , Journal of Antibiotics , 1981 , 34 , 58 – 63 . OpenUrl CrossRef PubMed 29. D. Hunziker , T. W. Yu , C. R. Hutchinson , H. G. Floss and C. Khosla , Journal of the American Chemical Society , 1998 , 120 , 1092 – 1093 . OpenUrl CrossRef Web of Science 30. C. J. Dutton , S. P. Gibson , A. C. Goudie , K. S. Holdom , M. S. Pacey , J. C. Ruddock , J. D. Bulock and M. K. Richards , Journal of Antibiotics , 1991 , 44 , 357 – 365 . OpenUrl CrossRef PubMed 31. ↵ Y. Zhuo , T. Zhang , Q. Wang , P. Cruz-Morales , B. Zhang , M. Liu , F. Barona-Gómez and L. Zhang , Biotechnol J , 2014 , 9 , 316 – 325 . OpenUrl CrossRef PubMed 32. ↵ J. Lau , D. E. Cane and C. Khosla , Biochemistry , 2000 , 39 , 10514 – 10520 . OpenUrl CrossRef PubMed Web of Science 33. ↵ J. Franke and C. Hertweck , Cell Chem Biol , 2016 , 23 , 1179 – 1192 . OpenUrl CrossRef PubMed 34. ↵ M. Grote and F. Schulz , ChemBioChem , 2019 , 20 , 1183 – 1189 . OpenUrl CrossRef PubMed 35. ↵ T. J. Erb , I. A. Berg , V. Brecht , M. Müller , G. Fuchs and B. E. Alber , Proc Natl Acad Sci U S A , 2007 , 104 , 10631 – 10636 . OpenUrl Abstract / FREE Full Text 36. T. J. Erb , V. Brecht , G. Fuchs , M. Müller and B. E. Alber , Proc Natl Acad Sci U S A , 2009 , 106 , 8871 – 8876 . OpenUrl Abstract / FREE Full Text 37. R. G. Rosenthal , M. O. Ebert , P. Kiefer , D. M. Peter , J. A. Vorholt and T. J. Erb , Nat Chem Biol , 2014 , 10 , 50 – 55 . OpenUrl CrossRef PubMed 38. ↵ M. C. Wilson and B. S. Moore , Nat Prod Rep , 2012 , 29 , 72 – 86 . OpenUrl CrossRef PubMed 39. ↵ Y. Yan , J. Chen , L. Zhang , Q. Zheng , Y. Han , H. Zhang , D. Zhang , T. Awakawa , I. Abe and W. Liu , Angew Chem Int Ed Engl , 2013 , 52 , 12308 – 12312 . OpenUrl CrossRef 40. ↵ Amanda J. Hughes and A. Keatinge-Clay , Chemistry & Biology , 2011 , 18 , 165 – 176 . OpenUrl CrossRef PubMed 41. ↵ I. Koryakina , J. McArthur , S. Randall , M. M. Draelos , E. M. Musiol , D. C. Muddiman , T. Weber and G. J. Williams , ACS Chemical Biology , 2013 , 8 , 200 – 208 . OpenUrl CrossRef PubMed 42. ↵ L. Laureti , L. J. Song , S. Huang , C. Corre , P. Leblond , G. L. Challis and B. Aigle , Proceedings of the National Academy of Sciences of the United States of America , 2011 , 108 , 6258 – 6263 . OpenUrl Abstract / FREE Full Text 43. ↵ L. Su , L. Hôtel , C. Paris , C. Chepkirui , A. O. Brachmann , J. Piel , C. Jacob , B. Aigle and K. J. Weissman , Nat Commun , 2022 , 13 , 515 . OpenUrl PubMed 44. ↵ L. Ray , T. R. Valentic , T. Miyazawa , D. M. Withall , L. J. Song , J. C. Milligan , H. Osada , S. Takahashi , S. C. Tsai and G. L. Challis , Nat Commun , 2016 , 7 , 13609 . OpenUrl CrossRef PubMed 45. ↵ D. Möller , S. Kushnir , M. Grote , A. Ismail-Ali , K. R. M. Koopmans , F. Calo , S. Heinrich , B. Diehl and F. Schulz , Lett Appl Microbiol , 2018 , 67 , 226 – 234 . OpenUrl CrossRef PubMed 46. ↵ L. Laureti , PhD thesis , Université de Lorraine , 2010 . 47. ↵ S. F. Altschul , W. Gish , W. Miller , E. W. Myers and D. J. Lipman , J Mol Biol , 1990 , 215 , 403 – 410 . OpenUrl CrossRef PubMed Web of Science 48. ↵ X. Pang , B. Aigle , J. M. Girardet , S. Mangenot , J. L. Pernodet , B. Decaris and P. Leblond , Antimicrob Agents Chemother , 2004 , 48 , 575 – 588 . OpenUrl Abstract / FREE Full Text 49. ↵ R. Bunet , L. Song , M. V. Mendes , C. Corre , L. Hotel , N. Rouhier , X. Framboisier , P. Leblond , G. L. Challis and B. Aigle , J Bacteriol , 2011 , 193 , 1142 – 1153 . OpenUrl Abstract / FREE Full Text 50. ↵ Y. A. Chan , A. M. Podevels , B. M. Kevany and M. G. Thomas , Nat Prod Rep , 2009 , 26 , 90 – 114 . OpenUrl CrossRef PubMed Web of Science 51. ↵ M. Myronovskyi and A. Luzhetskyy , Nat Prod Rep , 2016 , 33 , 1006 – 1019 . OpenUrl CrossRef PubMed 52. ↵ Y. Yan , J. Wu , G. Hu , C. Gao , L. Guo , X. Chen , L. Liu and W. Song , Synth Syst Biotechnol , 2022 , 7 , 887 – 899 . OpenUrl CrossRef PubMed 53. ↵ United States Pat ., US20120142622A1 , 2012 . 54. ↵ L. Song , L. Laureti , C. Corre , P. Leblond , B. Aigle and G. L. Challis , The Journal of Antibiotics , 2014 , 67 , 71 – 76 . OpenUrl CrossRef PubMed 55. ↵ K. Tunyasuvunakool , J. Adler , Z. Wu , T. Green , M. Zielinski , A. Žídek , A. Bridgland , A. Cowie , C. Meyer , A. Laydon , S. Velankar , G. J. Kleywegt , A. Bateman , R. Evans , A. Pritzel , M. Figurnov , O. Ronneberger , R. Bates , S. A. A. Kohl , A. Potapenko , A. J. Ballard , B. Romera-Paredes , S. Nikolov , R. Jain , E. Clancy , D. Reiman , S. Petersen , A. W. Senior , K. Kavukcuoglu , E. Birney , P. Kohli , J. Jumper and D. Hassabis , Nature , 2021 , 596 , 590 – 596 . OpenUrl CrossRef PubMed 56. ↵ E. J. Barreiro , A. E. Kümmerle and C. A. Fraga , Chem Rev , 2011 , 111 , 5215 – 5246 . OpenUrl CrossRef PubMed 57. ↵ G. Kosec , D. Goranovič , P. Mrak , S. Fujs , E. Kuščer , J. Horvat , G. Kopitar and H. Petkovic , Metab Eng , 2012 , 14 , 39 – 46 . OpenUrl CrossRef PubMed View the discussion thread. Back to top Previous Next Posted October 29, 2024. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Exploiting the inherent promiscuity of the acyl transferase of the stambomycin polyketide synthase for the mutasynthesis of analogues Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Exploiting the inherent promiscuity of the acyl transferase of the stambomycin polyketide synthase for the mutasynthesis of analogues Li Su , Yaouba Souaibou , Laurence Hôtel , Christophe Jacob , Peter Grün , Yan-Ni Shi , Alicia Chateau , Sophie Pinel , Helge B. Bode , Bertrand Aigle , Kira J. Weissman bioRxiv 2024.10.29.620781; doi: https://doi.org/10.1101/2024.10.29.620781 Share This Article: Copy Citation Tools Exploiting the inherent promiscuity of the acyl transferase of the stambomycin polyketide synthase for the mutasynthesis of analogues Li Su , Yaouba Souaibou , Laurence Hôtel , Christophe Jacob , Peter Grün , Yan-Ni Shi , Alicia Chateau , Sophie Pinel , Helge B. Bode , Bertrand Aigle , Kira J. Weissman bioRxiv 2024.10.29.620781; doi: https://doi.org/10.1101/2024.10.29.620781 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Synthetic Biology Subject Areas All Articles Animal Behavior and Cognition (7649) Biochemistry (17737) Bioengineering (13925) Bioinformatics (42059) Biophysics (21495) Cancer Biology (18643) Cell Biology (25576) Clinical Trials (138) Developmental Biology (13405) Ecology (19946) Epidemiology (2067) Evolutionary Biology (24370) Genetics (15626) Genomics (22551) Immunology (17769) Microbiology (40480) Molecular Biology (17209) Neuroscience (88782) Paleontology (667) Pathology (2843) Pharmacology and Toxicology (4835) Physiology (7662) Plant Biology (15177) Scientific Communication and Education (2047) Synthetic Biology (4304) Systems Biology (9838) Zoology (2272)